Sustained diabetes remission induced by FGF1 involves a shift in transcriptionally distinct AgRP neuron subpopulations

Nadia Aalling, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Petar V. Todorov, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Shad Hassan, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Dylan M. Belmont-Rausch, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Oliver Pugerup Christensen, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Claes Ottzen Laurentiussen, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Anja M. Jørgensen, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Kimberly M. Alonge, UW Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA, USA; McKnight Brain Institute, Department of Neuroscience, University of Florida, Gainesville, FL, USA.
Jarrad M. Scarlett, UW Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA, USA.
Zaman Mirzadeh, Department of Neurosurgery, Barrow Neurological Institute, Phoenix, AZ, USA.
Jenny M. Brown, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark.
Michael W. Schwartz, UW Medicine Diabetes Institute, Department of Medicine, University of Washington, Seattle, WA, USA.
Tune H. Pers, Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, Copenhagen, Denmark. Electronic address: tune.pers@sund.ku.dk.

Document Type

Article

Abstract

In rodent models of type 2 diabetes, a single intracerebroventricular (icv) injection of fibroblast growth factor 1 (FGF1) induces sustained remission of hyperglycemia. Overactive agouti-related peptide (AgRP) neurons, located in the hypothalamic arcuate nucleus, are a hallmark of diabetic states, and their long-term inhibition has been linked to FGF1's antidiabetic effects. To investigate the underlying mechanism(s), we performed single-nucleus RNA sequencing of the mediobasal hypothalamus at Days 5 and 14 post-injection in wild-type and diabetic (Lep) mice treated with FGF1 or vehicle. We found that AgRP neurons from Lep mice form a transcriptionally distinct, hyperactive subpopulation. By Day 5, icv FGF1 induced a subset of these neurons to shift toward a less active, wild-type-like state, characterized by reduced activity-linked gene expression that persisted through Day 14. Spatial transcriptomics revealed that this FGF1-responsive AgRP subset is positioned dorsally within the arcuate nucleus. The transcriptional shift was accompanied by increased transcriptional processes indicative of GABAergic signaling, axonogenesis, and astrocyte-AgRP and oligodendrocyte-AgRP interactions. These glial inputs involve astrocytic neurexins and the perineuronal net (PNN) component phosphacan, suggesting both intrinsic and extrinsic mechanisms underlie FGF1-induced AgRP silencing. Combined with evidence that FGF1 increases assembly in the arcuate nucleus, our findings reveal a cell-type-specific model for how FGF1 elicits long-term reprogramming of hypothalamic circuits to achieve diabetes remission.

Publication Date

12-9-2025

Publication Title

Molecular metabolism

E-ISSN

2212-8778

First Page

102300

PubMed ID

41371441

Digital Object Identifier (DOI)

10.1016/j.molmet.2025.102300

Link to Full Text

Share

COinS